Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 14/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29882957 | 1.00 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL29656231 | 0.83 | EGFR (0.53) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL6942722 | 0.83 | EGFR (0.53) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL7971026 | 0.79 | GRM1 (0.48) | MAP4K4EGFRGRM1 | |
| SCHEMBL1584799 | 0.79 | MAP4K4 (0.49) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL17732856 | 0.79 | MAP4K4 (0.54) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL17804471 | 0.79 | EGFR (0.50) | EGFRGRM1 | |
| SCHEMBL31026197 | 0.79 | MAP4K4 (0.49) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL17610601 | 0.75 | EGFR (0.48) | PI4KAPI4K2BPI4K2API4KBMAP4K4 | |
| SCHEMBL21318570 | 0.72 | MAP4K4 (0.66) | MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849734-B2 | Intermediates useful for preparing 4,6-diaminopyrido[5,4-d]pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-01 | — | — | US | disclosed |
| US-20040059114-A1 | Intermediates useful for preparing 4,6-diaminopyrido[5,4-d]pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040059114-A1 | Intermediates useful for preparing 4,6-diaminopyrido[5,4-d]pyrimidines | DPYD, DCK, DTYMK | PI4KA 47/4885PI4K2B 124/4885PI4K2A 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.